PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab.

被引：3
|
作者：
Ray-Coquard, Isabelle Laure
Harter, Philipp
Martin, Antonio Gonzalez
Cropet, Claire
Pignata, Sandro
Fujiwara, Keiichi
Marth, Christian
Vergote, Ignace
Mirza, Mansoor Raza
Colombo, Nicoletta
Rosenberg, Per
Maenpaa, Johanna Unelma
lauraine, Eric PujaDe
机构：
[1] GINECO Grp, Lyon, France
[2] Ctr Leon Berard, Lyon, France
[3] AGO Germany, Essen, Germany
[4] GEICO, Madrid, Spain
[5] MD Anderson Canc Ctr Madrid, Madrid, Spain
[6] GINECO, Lyon, France
[7] MITO, Naples, Italy
[8] GOTIC, Hidaka, Japan
[9] AGO Austria, Innsbruck, Austria
[10] Univ Hosp Leuven, BGOG, Leuven, Belgium
[11] Copenhagen Univ Hosp, NSGO, Copenhagen, Denmark
[12] MANGO, Milan, Italy
[13] NSGO, Linkoping, Sweden
[14] Univ Hosp, Linkoping, Sweden
[15] NSGO, Tampere, Finland
[16] GINECO, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.TPS5605
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5605
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Phase II OVARIO Study of niraparib plus bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab
    Hardesty, Melissa
    Krivak, Thomas
    Wright, Gail
    Hamilton, Erika
    Fleming, Evelyn
    Belotte, Jimmy
    Keeton, Erika
    Chen, Jian
    Clements, Aine
    Gray, Heidi
    Konecny, Gottfried
    Moore, Richard
    Richardson, Debra
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S17 - S17
  • [32] Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial
    Lorusso, Domenica
    Mouret-Reynier, Marie-Ange
    Harter, Philipp
    Cropet, Claire
    Caballero, Cristina
    Wolfrum-Ristau, Pia
    Satoh, Toyomi
    Vergote, Ignace
    Parma, Gabriella
    Nottrup, Trine J.
    Lebreton, Coriolan
    Fasching, Peter A.
    Pisano, Carmela
    Manso, Luis
    Bourgeois, Hugues
    Runnebaum, Ingo
    Zamagni, Claudio
    Hardy-Bessard, Anne-Claire
    Schnelzer, Andreas
    Fabbro, Michel
    Schmalfeldt, Barbara
    Berton, Dominique
    Belau, Antje
    Lotz, Jean-Pierre
    Gropp-Meier, Martina
    Gladieff, Laurence
    Lueck, Hans-Joachim
    Abadie-Lacourtoisie, Sophie
    Pujade-Lauraine, Eric
    Ray-Coquard, Isabelle
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (04) : 550 - 558
  • [33] Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)
    Ray-Coquard, I. L.
    Leary, A.
    Pignata, S.
    Cropet, C.
    Gonzalez Martin, A. J.
    Bogner, G.
    Yoshida, H.
    Vergote, I. B.
    Colombo, N.
    Maenpaa, J.
    Selle, F.
    Schmalfeldt, B.
    Scambia, G.
    Guerra Alia, E. M.
    Lefeuvre-Plesse, C.
    Belau, A.
    Lortholary, A.
    Gropp-Meier, M.
    Pujade-Lauraine, E.
    Harter, P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1396 - S1397
  • [34] OVARIO, A Phase 2 Study of Niraparib plus Bevacizumab in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy with Bevacizumab: Updated Analysis
    Hardesty, Melissa
    Krivak, Thomas
    Wright, Gail
    Hamilton, Erika
    Fleming, Evelyn
    Belotte, Jimmy
    Keeton, Erika
    Wang, Ping
    Clements, Aine
    Gray, Heidi
    Konecny, Gottfried
    Moore, Richard
    Richardson, Debra
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S27 - S28
  • [35] EFFICACY OF SUBSEQUENT CHEMOTHERAPY FOLLOWED BY PARP INHIBITOR MAINTENANCE IN PATIENTS WITH ADVANCED OVARIAN CANCER IN THE PHASE III PAOLA-1/ENGOT-OV25 TRIAL
    Marth, Christian
    Mouret-Reynier, Marie-Ange
    Lorusso, Domenica
    Cropet, Claire
    Harter, Philipp
    Guerra, Eva
    Matsumoto, Takashi
    Vergote, Ignace
    Colombo, Nicoletta
    Maenpaa, Johanna
    Lebreton, Coriolan
    De Gregorio, Nikolaus
    Mosconi, Anna Maria
    Rubio, Maria Jesus
    Bourgeois, Hugues
    Fasching, Peter A.
    Hardy-Bessard, Anne-Claire
    Denschlag, Dominik
    Pujade-Lauraine, Eric
    Ray-Coquard, Isabelle
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A21 - A21
  • [36] EFFICACY OF MAINTENANCE OLAPARIB PLUS BEVACIZUMAB BY BIOMARKER STATUS IN CLINICAL HIGHER- AND LOWER-RISK PATIENTS WITH NEWLY DIAGNOSED, ADVANCED OVARIAN CANCER IN THE PAOLA-1 TRIAL
    Harter, P.
    Petran, D.
    Scambia, G.
    Ortega, E.
    Tsibulak, I.
    Nagao, S.
    Vergote, I.
    Meunier, J.
    Priou, F.
    Sverdlin, R.
    Milenkova, T.
    Ray-Coquard, I.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A13 - A14
  • [37] Olaparib as Maintenance Treatment Following First-line Platinum-based Chemotherapy (PBC) in Patients With a Germline BRCA Mutation and Metastatic Pancreatic Cancer (mPC): Phase III POLO Trial
    Golan, T.
    Hammel, P.
    Reni, M.
    Van Cutsem, E.
    Macarulla, T.
    Hall, M. J.
    Park, J. O.
    Hochhauser, D.
    Arnold, D.
    Oh, D. Y.
    Reinacher-Schick, A.
    Tortora, G.
    Alguel, H.
    O'Reilly, E. M.
    McGuinness, D.
    Cui, K. Y.
    Schlienger, K.
    Locker, G. Y.
    Kindler, H. L.
    PANCREAS, 2019, 48 (10) : 1433 - 1434
  • [38] Olaparib (ola) plus bevacizumab (bev) as maintenance (mx) therapy in patients (pts) with newly diagnosed advanced ovarian carcinoma (OC): Japan subset of the PAOLA-1 trial
    Fujiwara, K.
    Fujiwara, H.
    Yoshida, H.
    Satoh, T.
    Yonemori, K.
    Nagao, S.
    Matsumoto, T.
    Kobayashi, H.
    Bourgeois, H.
    Harter, P.
    Mosconi, A. M.
    Palacio, I.
    Reinthaller, A.
    Fujita, T.
    Bloomfield, R.
    Pujade-Lauraine, E.
    Ray-Coquard, I. L.
    ANNALS OF ONCOLOGY, 2020, 31 : S1335 - S1336
  • [39] Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial
    Oh, D-Y.
    Golan, T.
    Hammel, P.
    Reni, M.
    Van Cutsem, E.
    Macarulla, T.
    Hall, M. J.
    Park, Oh
    Hochhauser, D.
    Arnold, D.
    Reinacher-Schick, A.
    Tortora, G.
    Alguel, H.
    O'Reilly, E. M.
    McGuinness, D.
    Cui, K. Y.
    Schlienger, K.
    Locker, G. Y.
    Kindler, H. L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [40] Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial
    Cremolini, Chiara
    Malmorino, Federica
    Bergamo, Francesca
    Aprile, Giuseppe
    Salvatore, Lisa
    Masi, Gianluca
    Dell'Aquila, Emanuela
    Antoniotti, Carlotta
    Murgioni, Sabina
    Allegrini, Giacomo
    Borelli, Beatrice
    Gemma, Donatello
    Casagrande, Mariaelena
    Granetto, Cristina
    Delfanti, Sara
    Di Donato, Samantha
    Schirripa, Marta
    Sensi, Elisa
    Tonini, Giuseppe
    Lonardi, Sara
    Fontanini, Gabriella
    Boni, Luca
    Falcone, Alfredo
    EUROPEAN JOURNAL OF CANCER, 2019, 109 : 175 - 182
12345